A Multicenter Phase Ii Trial of Nab-Paclitaxel in Combination with Capecitabine in Patients (Pts) with Her-2 Negative and Triple Negative Advanced Breast Cancer (Abc): an Interim Analysis
Mariangela Ciccarese(Ospedale Vito Fazzi), Saverio Cinieri(Ospedale A. Perrino), Roberto Bordonaro(Ospedale Garibaldi), Maria Rosachiara Forcignanò(Ospedale Vito Fazzi), Salvatore Pisconti(Ospedale SS. Annunziata), P. Cilenti(Casa Sollievo della Sofferenza), Evaristo Maiello(Casa Sollievo della Sofferenza), Gianluca Colucci, Palma Fedele(Ospedale A. Perrino), V. Lorusso(Gastroenterology Hospital "Saverio de Bellis"), Antonio Febbraro(Fatebenefratelli Hospital), Antonio Rinaldi, Giovanni Bozza(Centro di Riferimento Oncologico della Basilicata), Laura Orlando, Nicolò Borsellino(Ospedale Buccheri la Ferla Fatebenefratelli), S. Romito(Ospedali Riuniti di Foggia), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), P. Schiavone, Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368
First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial
|Journal of Clinical Oncology|2012|234
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
|Journal of Clinical Oncology|2022|231
Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis
|Annals of Oncology|2009|205